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The presence of vancomycin-resistant enterococci (VRE) was looked for in fecal samples from 104 healthy
volunteers (3 with hospital exposure), 100 selected hospitalized patients, and various environmental sources
(44 commercial chickens, 5 farm-raised chickens, 3 turkeys, and 2 chicken farm lagoon slurries). Five probiotic
preparations were also studied. No VRE with vanA or vanB genes were isolated from the healthy volunteers
without hospital exposure, environmental sources, or probiotic preparations. VRE with vanB were found in the
stools of 16% of the high-risk hospitalized patients and in one volunteer with hospital contact. All VRE
examined could be classified into one of two clones by pulsed-field gel electrophoresis. VRE from 11 of the
colonized patients were quantified and ranged from 103 to 106 CFU/g of stool. This study, in contrast to findings
in Europe, failed to find evidence of VanA- or VanB-type VRE in the community or environmental sources in
Houston, Texas, and suggests that these settings are not a likely source of VRE in hospitals in this geographic
area.
Vancomycin resistant enterococci (VRE) were isolated in
Europe in 1986 (28, 46) and in 1987 in the central United
States (37). In recent years, the nosocomial prevalence of VRE
in the United States has increased from 0.3% in 1989 to 7.9%
in 1993 (7), and clonally related isolates have often been ob-
served in different patients, including some hospitalized in
different cities (9, 31). In contrast to findings in the United
States, the presence of clinical isolates of VRE in European
hospitals is still rather infrequent (51), and great heterogeneity
has been reported among typed isolates from the nosocomial
setting (5, 8, 22, 36).
Three phenotypic classes of glycopeptide resistance have
been described: VanA, VanB, and VanC (3). Enterococcus
gallinarum and Enterococcus casseliflavus contain the species-
specific genes vanC1 and vanC2, respectively, which can confer
low to moderate levels of resistance (VanC phenotype) (29,
35). Acquired resistance to glycopeptides (VanA and VanB)
has been reported for Enterococcus faecalis, Enterococcus fae-
cium, Enterococcus raffinosus, Enterococcus avium, Enterococ-
cus durans, Enterococcus hirae, Enterococcus mundtii, E. galli-
narum, and E. casseliflavus (10, 15, 20, 26, 45, 47). E. faecium
has been the most often isolated species and VanA has been
the most often reported phenotype (7). Nonetheless, because
of difficulties in detecting some VanB-type VRE (41, 42) and
because some studies have been designed to detect the high
levels of resistance more characteristic of the VanA phenotype
(24, 25), VanB-type VRE could be more widespread than
previously thought.
Although major strides have been made toward understand-
ing the mechanism of vancomycin resistance (3) and the spread
of VRE within the nosocomial environment (31), the epide-
miology of VRE outside the hospital setting remains less well
defined. In Europe, investigators have found VRE in healthy
volunteers (22, 24, 48), sewage (23, 44), and animal sources,
including uncooked chickens purchased from retail outlets (1,
4, 25). However, the presence of VRE in community and
environmental settings in the United States has not been de-
fined.
Following the first isolation of VRE in our hospital in June
1994, we initiated a study to determine if spread of this organ-
ism to other patients could be documented and to determine if
the outpatient community was a likely source. In this study, we
surveyed fecal samples of hospitalized patients, healthy volun-
teers, and different environmental sources including commer-
cial chickens, farm-raised chicken and turkeys, chicken farm
lagoon slurries, and probiotic preparations from the Houston,
Texas, metropolitan area, for the presence of VRE and clas-
sified these VRE with respect to the type of vancomycin resis-
tance gene and clonal relatedness.
MATERIALS AND METHODS
Sources of bacterial isolates. Between June 1994 and July 1996, single-stool
specimens were obtained from the following sources: (i) healthy volunteers, 18 to
45 years of age, without prior medical illness or recent antimicrobial exposure
(n 5 104; 101 of 104 had no hospital exposure); (ii) inpatients at a tertiary care
university-affiliated hospital who had been hospitalized for at least 8 days (n 5
100); samples included fecal specimens submitted to the microbiology laboratory
for other purposes (n 5 47), stool samples from patients in the same units in
which clinical isolates of VRE had been recovered (n 5 14), and stool samples
from patients treated with vancomycin (n 5 39); and (iii) freshly slaughtered
farm-raised chickens (n 5 5) and turkeys (n 5 3). Cultures were also obtained
from 44 fresh chickens purchased from six different local grocery stores (Hous-
ton, Texas), two samples from chicken farm lagoon slurries in Texas, and five
probiotic preparations processed in geographically diverse locations (Super Car-
rot Acidophilus, Source Naturals, Inc., Scotts Valley, Calif.; Power Dophilus,
Country Life, Hauppauge, N.Y.; Protec Acidophilus; Natural Factors, Santa
Barbara, Calif.; Children’s PB8, Nutrition Now, Portland, Oreg.; and PrimeLife,
Klaire Laboratories, Inc., San Marcos, Calif.).
Informed consent was obtained from all participating volunteers. This study
was approved by the University of Texas Committee for the Protection of Human
Subjects.
Sample processing. For human fecal samples from 104 healthy volunteers and
61 hospitalized patients, 0.5 g of feces was suspended in 4.5 ml of normal saline
and serially 10-fold diluted. A 100-ml aliquot of the dilutions was used to inoc-
ulate Streptococcus faecalis medium (SF agar; Difco Laboratories, Detroit,
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Mich.) containing 6 mg of vancomycin (Van) per ml; CNA agar (Difco Labora-
tories) containing 6 mg of vancomycin per ml plus 10 mg of amphotericin per ml;
and SF agar and CNA plates without antibiotics. The latter two were used as
controls for detection of any enterococci. Thirty-nine fecal specimens from
hospitalized patients were plated directly on the above media. The plates were
incubated at 378C and examined at 24, 48, and 72 h. For 40 of the samples
isolated from healthy volunteers, a 100-ml aliquot of the above suspension was
also inoculated into 4.5 ml of SF broth plus 6 mg of vancomycin per ml. For 10
of the samples from normal volunteers, 0.5 g was inoculated into 4.5 ml of brain
heart infusion (BHI) (Difco Laboratories) broth, SF broth, and SF broth plus 6
mg of vancomycin per ml. Tubes were incubated at 378C for 48 h with shaking.
Aliquots of 100 ml from the tubes showing growth were then plated on the above
media. Five colonies of each morphology seen on plates containing antibiotics
were subcultured onto BHI agar plus 6 mg of vancomycin for identification and
further confirmation of vancomycin resistance. Only one stool specimen per
person and only one isolate of a given species per specimen were evaluated.
For animal sources, the whole eviscerated cavity was swabbed and plated on
the above media, and some samples were also plated on SF containing kanamy-
cin (2,000 mg/ml), streptomycin (1,000 mg/ml), or gentamicin (500 mg/ml). Ali-
quots of 200 ml from chicken farm lagoons were plated on the same media.
Probiotics were pulverized, and 0.5 g was inoculated into 5 ml of BHI broth.
Subcultures from tubes showing growth were plated on the above media.
Vancomycin was kindly provided by Eli Lilly & Co. (Indianapolis, Ind.);
kanamycin, streptomycin, and gentamicin were purchased from Sigma Chemical
Co. (St. Louis, Mo.).
Susceptibility testing. MICs of vancomycin, teicoplanin, ampicillin, and clin-
damycin were determined by following the National Committee for Clinical
Laboratory guidelines (33). Susceptibility to tetracycline, chloramphenicol, and
ciprofloxacin was determined by disk diffusion (34). High-level resistance to
aminoglycosides was determined by plating onto BHI agar containing 2,000 mg of
streptomycin per ml and BHI agar containing 500 mg of gentamicin per ml (33).
Teicoplanin and ciprofloxacin were kindly provided by Marion Merrell Dow
(Cincinnati, Ohio) and Miles Laboratories Inc. (West Haven, Conn.), respec-
tively. Ampicillin, tetracycline, and chloramphenicol were purchased from Sigma
Chemical Co., and clindamycin was purchased from Boehringer Mannheim Inc.
(Indianapolis, Ind.).
The control strains used were Staphylococcus aureus ATCC 29213, E. faecalis
ATCC 29212, Escherichia coli ATCC 25922, E. faecalis A256 (40), E. faecium
D366 (50), E. faeciumD399 (39), E. gallinarumUCLAII (49), and E. casseliflavus
C11 (kindly provided by David M. Shlaes).
Genetic characterization of vancomycin resistance. The presence of DNA
homologous to vanA, vanB, vanC1, and vanC2 genes was tested by colony lysis
hybridization under high-stringency conditions (38). Intragenic probes for vanA
and vanB were generated by PCR from E. faecalisA256 and E. faeciumD366 (40,
50), respectively, by using two primers selected from previously published se-
quences (16, 18); (vanA, F/59-GCAAGTCAGGTGAAGATGG-39 and R/59-AC
CTCGCCAACAACTAACGC-39; vanB, F/59-ACCCTGTCTTTGTGAAGCCGG
CAC-39 and R/59-CAAAAAAAGATCAACACGAGCAAGCCC-39). Oligonucle-
otides chosen from published sequences were used asvanC1 and vanC2 probes (17,
35) (vanC1: 1ATGGGAATCGCTAGTGC; vanC2: 1CATTGGCGTACAAA
GTGC).
Radiolabeled PCR fragments representing vanA and vanB were prepared by
incorporation of a-32P-dCTP-labeled deoxyribonucleotides with a random
primed DNA labeling kit in accordance with the manufacturer’s instructions
(Boehringer Mannheim). Oligonucleotide probes for vanC1 and vanC2 were end
labeled with [g-32P]dATP (38).
PFGE. Genomic DNA preparation and conditions for pulsed-field gel elec-
trophoresis (PFGE) were performed as described by Murray et al. (32), and
preparations were digested with SmaI (New England Biolabs, Beverly, Mass.).
Identification. Strains were presumptively identified as enterococci by colony
morphology and the results of testing for catalase production, hydrolysis of
esculin, growth in 6.5% NaCl, and hydrolysis of L-pyrrolydonyl-b-naphtylamide
(Difco Laboratories) (19). Further identification was performed by standard
biochemical tests (19) and API 20STREP (BioMerieux, Plainview, N.Y.).
To corroborate the identification to species level, the isolates were also tested
for the presence of genes coding for GyrA and AAC(69)-Ii, derived from E.
faecalis and E. faecium (13, 27), respectively, by using colony lysis hybridization
and high-stringency conditions (38). Intragenic probes for gyrA and for aac(69)-Ii
were generated by PCR from E. faecalis OG1RF (ATCC 47077) and from E.
faecium GE1 (ATCC 51558), respectively, by using the following primers: for
aac(69)-Ii, F/59-GCGGTAGCAGCGGTAGACCAAG-39 and R/59-GCATTTG
GTAAGACACCTACG-39; for gyrA, F/59-CGGGATGAACGAATTGGGTGT
GA-39 and R/59-AATTTTACTCATACGTGCTTCGG-39. Radiolabeled probes
for gyrA and aac(69)-Ii were prepared as described above. The use of these
probes for identification purposes has been previously reported (12, 13).
RESULTS
Enterococci were isolated from the feces of 75% of healthy
volunteers and from 80% of hospitalized patients. Vancomy-
cin-resistant gram-positive organisms other than enterococci
were recovered from 42 and 39% of the healthy volunteers and
the inpatient groups, respectively; further identification was
not performed. VRE were isolated from 16 of the 100 (16%)
selected inpatients studied (6 of whom had prior known infec-
tions by VRE). Twelve of these patients (75%) had severe
underlying diseases, and 10 (63%) had been treated with in-
travenous vancomycin in the previous 2 months. In 11 colo-
nized patients, VRE were quantified and ranged from 103 to
106 CFU/g of stool, constituting less than 1% of the entero-
coccal flora. VRE could not be quantified in five samples
because they had been submitted on a swab. VRE were found
in two healthy volunteers without hospital exposure and in one
with hospital exposure. VRE were usually recovered on SF
agar containing 6 mg of vancomycin per ml after 48 to 72 h of
incubation and on CNA containing 6 mg of vancomycin per ml
at 24 h.
VRE were identified as E. faecalis (three isolates) and E.
faecium (nine isolates) in the hospitalized group; four VRE
were not saved for further characterization. All of these VRE
were susceptible to teicoplanin and hybridized to the vanB
probe but not to the vanA, vanC1, or vanC2 intragenic probe
(Table 1). The E. faecalis isolates (vancomycin MICs, 512 mg/
ml; teicoplanin MICs, #0.25 mg/ml) were susceptible to ampi-
cillin (MICs, 1 to 2 mg/ml) and resistant to clindamycin (MICs,
.16 mg/ml) and ciprofloxacin (by disk) and highly resistant to
gentamicin and streptomycin. The E. faecium strains (vanco-
mycin MICs, 32 to 256 mg/ml; teicoplanin MICs, 0.5 mg/ml)
were resistant to ampicillin (MICs, 64 to 128 mg/ml), clinda-
mycin (MICs, .16 mg/ml), ciprofloxacin (by disk), and tetra-
cycline (by disk) and highly resistant to streptomycin. The two
VRE isolated from stools of the healthy volunteers with no
hospital exposure were identified as E. gallinarum and hybrid-
ized to the vanC1 probe but not to the vanA, vanB, or vanC2
probe. The VRE isolate recovered from a healthy volunteer
with hospital exposure hybridized to the vanB probe and was
identified as E. faecalis.
All E. faecalis isolates, including the isolate recovered from
a healthy volunteer with hospital exposure, and all E. faecium
isolates were classified as belonging to a single clone per spe-
cies by PFGE (pattern 1 for E. faecalis and pattern 2 for E.
faecium) (Fig. 1). E. faecalis isolates showed a pattern of SmaI-
digested genomic DNA more similar to that typical of E. fae-
cium than E. faecalis (all fragments less than 350 kb) as pre-
viously reported (12) (Fig. 1). These strains hybridized to the
E. faecalis gyrA probe but not to the E. faecium aac(69)-Ii
probe, corroborating their classification as E. faecalis (12).
None of the VRE recovered from animal sources and
chicken farm lagoons hybridized to the vanA or vanB probe,
although E. gallinarum isolates which hybridized to the vanC1
probe were isolated. Also, a number of E. faecalis and E.
faecium highly resistant to aminoglycosides (kanamycin, strep-
tomycin, and/or gentamicin) were detected.
Enterococci were recovered from all probiotic preparations
studied; however, no VRE were found.
DISCUSSION
VRE have been increasingly reported in recent years, al-
though the percent varies widely depending on the geographic
location and the setting (31, 51). In Europe, the isolation of
VRE from healthy volunteers, animals, and environmental
sources indicates that these organisms are part of the normal
human flora and suggests that the food chain may be the origin
of VRE in these countries (1, 4, 22, 23, 25, 44, 48). The
presence of VRE in environmental and community settings in
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the United States remains largely unknown, although nosoco-
mial outbreaks are commonly reported (6, 9, 21, 31).
Although we did not determine the overall incidence of
VRE in our hospital, their presence in 16% of high-risk pa-
tients and the demonstration that all isolates tested belonged
to one of only two clones is similar to results of other reports
in this country (6, 9, 21, 31). Moreover, in the same period as
this study, other clinical isolates of E. faecalis (six isolates) and
E. faecium (three isolates) with the same SmaI-digested
genomic DNA patterns described here were recovered at dif-
ferent hospitals in Houston, and the one VRE isolate from the
healthy volunteer with hospital exposure was found to be an E.
faecalis isolate of pattern 1, indicating intra- and interhospital
transmission of these two strains.
Despite a number of studies of VRE in the nosocomial
setting, including those implicating fecal contamination of en-
vironmental objects (6, 30), little information on the concen-
tration of VRE in feces is known. We found that the counts of
VRE in 11 colonized patients (6 of whom had been treated
with vancomycin in the previous 2 months) ranged from 103 to
106 CFU/g of fecal sample. Up to 106 to 108 CFU of VRE per
g were found in healthy Belgian volunteers after oral glyco-
peptide administration, while very low concentrations were
found in stool specimens of community-based Belgian volun-
teers without hospital or glycopeptide exposure (48). The large
numbers of VRE observed in our hospitalized patients and in
the volunteers after glycopeptide administration (48) might
result in an increased risk of nosocomial transmission of these
VRE as well as spread of this resistance to other species in the
intestinal flora.
The absence of vanA or vanB VRE in the healthy volunteers
in Houston who lacked hospital contact contrasts with results
of several studies performed in Europe in which 2 to 28% of
community-based persons without previous hospital or glyco-
peptide exposure have been reported to be colonized by VRE
(22, 24, 48). Comparison of the data should be done cautiously,
however, since different media (Enterococcosel, kanamycin-
aesculin-azide, CNA, and BHI), different concentrations of
antibiotics, and different plating or enrichment methods were
used in each of these studies, and this might result in the
differences in the recovery rates (22, 24, 48). In the study by
van der Auwera et al., VanA-type VRE were isolated from the
stools of 28% of healthy volunteers by directly plating on CNA
containing 16 mg of vancomycin per ml, and the authors were
able to detect low numbers of organisms (48). Although SF has
not previously been reported for detection of VRE, all our
isolates were detected on both CNA and SF supplemented
with vancomycin, suggesting that either medium can be used
for this purpose. CNA detected VRE earlier than did SF, but
SF has the advantage in that overgrowth of yeast- and vanco-
mycin-resistant organisms other than enterococci is unusual
and enterococcal colonies can be easily differentiated.
In agreement with other studies performed with animals in
the United States (26, 43), we did not recover VRE from
animal sources. This might be due to the fact that in the United
States, in contrast to Europe, glycopeptides are not used in
animal feeds. In some European countries, the glycopeptide
avoparcin is used for this purpose, and it has been demon-
strated as a risk factor for VRE (24, 25). Although the size of
our animal sample (n5 52) might represent a limitation of this
study, Bates et al. isolated VRE (4) in a large percentage of
samples studied (22 of 52 farm-raised animals and from 5 of 5
uncooked chickens). In other studies, the number of total
samples evaluated was not specified (24, 25). The food chain
has not clearly been demonstrated to be a source of VRE
acquisition in the United States, but this possibility cannot be
FIG. 1. PFGE of SmaI-digested genomic DNA from vanB-containing E.
faecium (pattern 2) (lanes 1 to 4 from left) and from vanB-containing E. faecalis
(pattern 1) (lanes 5 to 8). Lane 9 shows successively larger concatemers of a
lambda phage DNA ladder standard (48.5 to 1,000 kb). Each lane represents an
independent isolate corresponding to a different patient.
TABLE 1. Fecal carriage of enterococci and VRE among persons and environmental sources examined
Population
(no. of isolates)
Enterococci
(%)
No. of
VRE Species
PFGE
result
No. of strains hybridizing to the following probes:
vanA vanB vanC1 vanC2 E. faecalisgyrAa
E. faecium
aac(69)-Iia
Hospitalized (100) 75 3 E. faecalis Pattern 1 0 3 0 0 3 0
9 E. faecium Pattern 2 0 9 0 0 0 9
4 Not saved
Community (104) 80 2 E. gallinarum NTb 0 0 2 0 NT NT
1c E. faecalis Pattern 1 0 1 0 0 1 0
Animal (52) 100 16 E. gallinarum NT 0 0 16 0 NT NT
Farm lagoon (2) 100 2 E. gallinarum NT 0 0 2 0 NT NT
Probiotic (5) 100 0
a Different enterococcal species (32 E. faecium, 19 E. faecalis, 2 E. casseliflavus, 2 E. gallinarum, 2 E. solitarius, 2 E. hirae, 1 E. mundtii, and 1 E. raffinosus isolates)
were also tested with aac(69)-li and gyrA probes. All E. faecalis strains hybridized to the gyrA probe but not to the aac(69)-Ii probe. All E. faecium strains hybridized
to the aac(69)-Ii probe but not to the gyrA probe. None of the non-E. faecalis strains hybridized to the gyrA probe, and none of the non-E. faecium strains hybridized
to the aac(69)-li probe.
b NT, not tested.
c From a healthy volunteer with hospital exposure.
VOL. 40, 1996 VRE FROM SOURCES IN UNITED STATES 2607
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
eliminated. Recently, a vancomycin-resistant E. hirae strain has
been isolated from creek water, but whether this creek was
close to an animal source or to a hospital setting is unknown
(26). Also, a VanA E. faecium strain has been recovered from
dry dog food (14).
Together with our failure to recover enterococci from non-
hospitalized patients or environmental sources, we did not find
VRE in different brands of probiotics. However, this is another
possible route for the introduction of VRE to the community,
since an isolate containing the vanB gene recovered from a
bacterial preparation has been described previously (2).
VRE have been recovered from a large number of samples
by a direct plating method or broth enrichment in a highly
selective medium in some studies (4, 25, 48). Despite the use of
these methods in our study, we failed to find evidence of vanA
or vanB VRE in community or environmental sources. Al-
though the use of a direct plating method on antibiotic-con-
taining medium has been shown to increase the recovery rate
of resistant enterococci (11), Klare et al. have recently re-
ported isolation of VRE only after broth enrichment in anti-
biotic-free medium in some of the samples they studied, sug-
gesting that with the use of selective media, low numbers of
organisms might be missed (24). Further studies to establish an
optimal medium and method for the recovery and detection of
VRE are necessary.
The results of this study indicate that in our geographic area,
enterococci with acquired vancomycin resistance are rare to
nonexistent in community sources and thus these are unlikely
sources of VRE now found in the hospital setting. However,
our findings represent sampling of sources restricted to the
greater Houston metropolitan area and may not be represen-
tative of other areas, in particular locations where VRE have
been long established in the hospital environment or where
introduction via the food chain may be more likely.
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